

## Supplementary File 5

Patients with *BRCA1/2* mutation had a significantly higher risk of contralateral breast cancer than patients with wild type.<sup>[1]</sup> Evidence supports that contralateral prophylactic mastectomy may reduce contralateral breast cancer incidence and associated mortality in patients with *BRCA1/2* mutation breast cancer.<sup>[2-4]</sup>

1. Yoon KH, Chae S, Kang E, Shin HC, Kim JH, Kim IA, *et al.* Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer. *J Breast Cancer* 2019;22:587-598. doi: 10.4048/jbc.2019.22.e47.
2. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, *et al.* Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999;340:77-84. doi: 10.1056/NEJM199901143400201.
3. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, *et al.* Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. *J Natl Cancer Inst* 2001;93:1633-7. doi: 10.1093/jnci/93.21.1633.
4. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, *et al.* Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. *Ann Surg Oncol* 2007;14:3335-44. doi: 10.1245/s10434-007-9449-x..